News News Details

Efung Honor| The Power of Youth in Hard-Tech Arena! Effice Capital's CEO Zhu Pai Named to Qimingpia

Date: 2026-09-02
Views: 1



Today, Qimingpian officially released its "2026 China U35 Outstanding Young Investors" list, and Mr. Zhu Pai, CEO of Effice Capital, has been honored on this prestigious roster.


In 2026, the primary market is taking shape in a new landscape defined by "deep tech innovation, value consolidation, and industrial symbiosis." AI, humanoid robotics, semiconductors, commercial aerospace, healthcare, and hard tech have emerged as the market's core pillars. Technological moats, commercial viability, and long-term industrial value have become the industry's shared benchmarks.


From the domestic breakthrough of high-end manufacturing and critical components, to the technological leap of generative AI and innovative biomedicine, and further to the refined operations and global expansion of emerging brands—every step forward in industry evolution is driven by the forward-looking strategies and professional partnership of investors and financial advisors. They irrigate the soil of innovation with capital and bridge resources with expertise, serving as an indispensable backbone of the tech-innovation ecosystem.


Though market tides keep shifting, the essence of venture capital remains unwavering: depth of expertise defines vision, and steadfast conviction delivers value. It is precisely this commitment that has earned Mr. Zhu Pai, CEO of Effice Capital, a place on Qimingpian's "2026 China U35 Outstanding Young Investors" list.


Looking ahead, Effice Capital will continue to uphold its long-term, industry-rooted investment philosophy, walking alongside exceptional entrepreneurs through market cycles and fostering shared growth, as we contribute to the high-quality development of China's hard-tech and innovative biopharma sectors.


【Disclaimer】


The information contained herein represents solely the views of the Company based on current publicly available information and data provided by its portfolio companies. It does not constitute any form of investment advice, medical recommendation, or guarantee of specific enterprise performance. All investments carry risks, and readers should exercise caution and make independent judgments based on public information. Unauthorized reproduction or commercial use is strictly prohibited.


Related News / Recommended news More
2026 - 03 - 24
In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme &quo...
2026 - 03 - 25
Frontier Biotechnologies Inc. (“Frontier Biotechnologies” or the “Company”) recently entered into an exclusive licensing agreement with global biopharmaceutical company GlaxoSmithKline (“GSK”). Under the agreement, GSK will obtain exclusive worldwide rights for the development, manufacturing, and commercialization of two siRNA pipeline assets. One candidate drug has reached the Investigational New...
2026 - 03 - 06
Oryzogen's Orumin® Phase IV Clinical Trial Completes First Dosing | Portfolio NewsOn March 5, 2026, the Phase IV clinical study of Oryzogen's recombinant human albumin (rice-derived) Orumin®, evaluating its "safety and efficacy in patients with hypoalbuminemia and/or hypovolemia requiring emergency treatment," achieved its first patient enrollment and completed the init...
2026 - 03 - 05
The year 2026 marks the beginning of the 15th Five-Year Plan period. Recently, the 11th batch of the “Outstanding Domestic Medical Equipment Product Catalogue” was officially released. Viestar’s independently developed BIOPSEE® Confocal Laser Endomicroscope and BIOPSEE® Ultra-Thin Probe-based Confocal Laser Endomicroscope were prominently selected. This recognition makes JWS Medical the ...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务